0000950170-24-015465.txt : 20240214
0000950170-24-015465.hdr.sgml : 20240214
20240214185643
ACCESSION NUMBER: 0000950170-24-015465
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240212
FILED AS OF DATE: 20240214
DATE AS OF CHANGE: 20240214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SEIDENBERG BETH C
CENTRAL INDEX KEY: 0001184592
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41947
FILM NUMBER: 24641369
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kyverna Therapeutics, Inc.
CENTRAL INDEX KEY: 0001994702
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 831365441
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5980 HORTON STREET
STREET 2: SUITE 550
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: 5106268331
MAIL ADDRESS:
STREET 1: 5980 HORTON STREET
STREET 2: SUITE 550
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
4
1
ownership.xml
4
X0508
4
2024-02-12
0001994702
Kyverna Therapeutics, Inc.
KYTX
0001184592
SEIDENBERG BETH C
C/O KYVERNA THERAPEUTICS, INC.
5980 HORTON ST., STE 550
EMERYVILLE
CA
94608
true
false
true
false
false
Common Stock
2024-02-12
4
C
false
3787940
A
3787940
I
See Footnote
Common Stock
2024-02-12
4
C
false
735984
A
735984
I
See Footnote
Series A-1 Redeemable Convertible Preferred Stock
2024-02-12
4
C
false
4401771
0
D
Common Stock
967188
0
I
See Footnote
Series A-2 Redeemable Convertible Preferred Stock
2024-02-12
4
C
false
8830901
0
D
Common Stock
1940388
0
I
See Footnote
Series B Redeemable Convertible Preferred Stock
2024-02-12
4
C
false
4006624
0
D
Common Stock
880364
0
I
See Footnote
Series B Redeemable Convertible Preferred Stock
2024-02-12
4
C
false
3349538
0
D
Common Stock
735984
0
I
See Footnote
Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration.
Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any.
Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, the Reporting Person and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any.
The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering.
By: /s/ Ryan Jones, as Attorney-in-Fact
2024-02-14